In AF or VTE, acenocoumarol or phenprocoumon dosing by genotype did not affect time in therapeutic range
Authors: Andrew Dunn
Journal: Annals of Internal Medicine (2014)

ACP Journal Club18 March 2014In AF or VTE, acenocoumarol or phenprocoumon dosing by genotype did not affect time in therapeutic rangeAndrew Dunn, MD, SFHM, MPH, FACPAndrew Dunn, MD, SFHM, MPH, FACPMount Sinai Health System, New York, New York, USA (A.D.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-160-6-201403180-02010 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationVerhoef TI, Ragia G, de Boer A, et al; EU-PACT Group. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med. 2013;369:2304-12. https://pubmed.ncbi.nlm.nih.gov/24251360Clinical Impact RatingsCardiology: Hematology: References1 Voora D, McLeod HL, Eby C, Gage BF. The pharmacogenetics of coumarin therapy. Pharmacogenomics. 2005;6:503-13. [PMID: 16014000] Google Scholar2 Anderson JL, Horne BD, Stevens SM, et al; Couma-Gen Investigators. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007;116:2563-70. [PMID: 17989110] Google Scholar3 Burmester JK, Berg RL, Yale SH, et al. A randomized controlled trial of genotype-based coumadin initiation. Genet Med. 2011;13:509-18. [PMID: 21423021] Google Scholar4 Gong IY, Tirona RG, Schwarz UI, et al. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood. 2011;118:3163-71. [PMID: 21725053] Google Scholar5 Kirchheiner J, Ufer M, Walter EC, et al. Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers. Pharmacogenetics. 2004;14:19-26. [PMID: 15128047] Google Scholar6 Takahashi H, Wilkinson GR, Nutescu EA, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics. 2006;16:101-10. [PMID: 16424822] Google Scholar7 Holbrook A, Schulman S, Witt DM, et al; American College of Chest Physicians. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e152S-84S. [PMID: 22315259] Google Scholar8 Patrick AR, Avorn J, Choudry NK. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2009;2:429-36 [PMID: 20031873] Google Scholar Author, Article, and Disclosure InformationAffiliations: Mount Sinai Health System, New York, New York, USA (A.D.)This article was published at Annals.org on 4 March 2014. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoWarfarin dosing by genotype did not improve time in therapeutic range Andrew Dunn In AF or VTE, warfarin dosing by genotype improved time in therapeutic range but not clinical outcomes Andrew Dunn Metrics 18 March 2014Volume 160, Issue 6Page: JC10KeywordsAtrial fibrillationClinical geneticsClinical trialsHemorrhagePharmacogeneticsThromboembolismVenous thromboembolismVitamin K ePublished: 18 March 2014 Issue Published: 18 March 2014 Copyright & PermissionsCopyright © 2014 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...